A judge has refused to stay a fight between the tax office and software company Oracle over royalties, finding determination of the dispute will guide 15 other cases.
Samsung Bioepis can’t get indemnity costs from Janssen Biotech after it surrendered patents for Crohn’s disease drug Stelara and filed a fresh case based on new patents for the drug.
A judge has issued a self-executing order for the dismissal of a patent infringement lawsuit against Monster Energy if the inventor who brought the case fails to pay $350,000 in security for the beverage giant’s costs within two weeks.
The security sum sought by Monster Energy from an inventor suing the beverage giant for patent infringement was “manifestly excessive”, a judge has said, and was based on an estimate of costs that included the fees of three solicitors and two barristers at an interlocutory hearing.
Monster Energy has hit back at an inventor’s claim it infringed his intellectual property by using his method for laser-etched branded pull tabs on cans, saying the invention is obvious.
An inventor who claims Monster Energy infringed his patent for laser etched pull tabs is fighting the beverage giant’s bid for $150,000 in security for costs, saying its estimates were “monstrous”.
A judge has thrown out competing appeals of a decision finding Pfizer’s patent for its post-operative injectable painkiller Dynastat is valid and that Australian drug maker Juno Pharmaceuticals infringed the patent by selling generic versions of the drug in Australia.
Explosives manufacturer Orica is closer to taking Dyno Nobel to court for allegedly infringing three of its explosives patents, filing proceedings to get more information about its rival’s CyberDet wireless detonator device.
Two of the world’s largest manufacturers of explosives have taken their fight over three patents for a detonation device to the Federal Court.
A judge has found Pfizer’s patent for its post-operative injectable painkiller Dynastat is valid and that Australian drug maker Juno Pharmaceuticals infringed the patent by selling generic versions of the drug in Australia.